Women don't let the eyebrows be shaved!

In the era of global innovation and development, women have become an important force in promoting progress in various fields.

In the initial stage, women’s responsibility is to take care of their families.

Focusing on the medical and pharmaceutical industry, the proportion of female entrepreneurs and executives has been increasing in recent years.

Chinese pharmaceutical entrepreneur

01

Zhong Huijuan

President of Hexion Pharmaceuticals

(Hausen Pharmaceuticals)

Zhong Huijuan, after graduating from a chemistry major in 1982, became an ordinary middle school chemistry teacher.

After the domestically produced antibiotic product "Meifeng", exclusively produced by Hausen, was put on the market in 1997, its annual sales exceeded 100 million yuan, but Zhong Huijuan was not satisfied with this.

With the company's listing on the Hong Kong Stock Exchange, Zhong Huijuan, the female head behind the scenes, soared in value and became China's "first sister of a pharmaceutical company.

02

Du Ying

Chairman of Zai Lab

Du Ying, after graduating from the University of Cincinnati with a PhD in Biochemistry in 1994, joined the multinational veteran pharmaceutical company Pfizer, from a researcher to a management level.

In 2002, Du Ying returned to China and started her entrepreneurial journey.

03

Zhao Ning

Co-founder of WuXi AppTec

Zhao Ning, after obtaining a doctorate in organic chemistry from Columbia University in the United States, has worked in scientific research and management in many multinational pharmaceutical companies such as Bristol-Myers Squibb, and has accumulated rich medical experience.

In 2011, Zhao Ning fully took over the company’s global human resources work.

04

Mao Huihua

Co-founder of CanSino Bio

Mao Huihua is the first batch of doctors after the reform and opening up.

In 2009, Mao Huihua, Yu Xuefeng, Zhu Tao, and Qiu Dongxu, together with the four returned doctoral groups who had served as senior executives of multinational pharmaceutical companies, founded Cansino Biotechnology Co.

05

Fan Minhua

Chairman of Puli Pharmaceuticals

Fan Minhua is hailed as one of the entrepreneurs in the industry that "China knows best about European and American cGMP certification".

Fan Minhua pays attention to scientific research, encourages independent research and development, and leads the company team to successfully develop a series of product lines in various fields such as anti-allergic, pediatrics, antipyretic and analgesic, and cultivated domestic well-known brands such as "Fubiding" and "Nofodin" Beginning in 2004, Puli Pharmaceuticals has pulled out all the old hardware facilities and rebuilt it, and built new injection production lines in accordance with European and American standards to prepare for the stricter management of overseas injections in the future.

Head of a multinational pharmaceutical company

01

Zhang Ying

President of Novartis Pharmaceuticals China

Zhang Ying joined Novartis in March 2011.

Novartis's expectation of Zhang Ying is to bring new weather and changes to Novartis China, such as stabilizing the organizational structure and bringing in new products.

02

Zhou Hong

President of Roche Pharmaceuticals China

Zhou Hong, a twelve-year-old woman from Wenzhou living in Germany, received both Chinese and Western education.
After obtaining a master's degree in business from the Berlin School of Economics in Germany in 1996, she worked for Deloitte, Schering, Bayer and other companies.
She has more than 20 years of focus.
A career in the medical and health field.
Joined Roche in 2015 as the general manager of Roche Pharmaceuticals China.

Under her leadership, Roche China quickly formed a drug supply assurance working group, created a drug purchase map covering various tumor diseases, conducted online disease science, launched a one-stop platform for caring for cancer patients, and provided end-to-end real-time medical information.
It is worth mentioning that, in the context of the decline in Roche's global performance, the mainland China and Hong Kong markets have risen steadily, with an annual growth rate of 8% last year.

03

Qi Xin

General Manager of Prescription Drugs and Vaccines, GlaxoSmithKline China

Qi Xin graduated from Shanghai Jiaotong University School of Medicine, and has worked for Squibb, Pfizer, Sanofi, Merck and many foreign companies.
In 2004, he joined GSK China as the marketing director of the vaccine business, and later served as the general manager of the hepatitis business department, digital marketing and commercial The leader of the excellent team was later appointed as the general manager of GSK China Hong Kong and Macau.
In 2019, he was promoted to vice president of GSK and general manager of vaccines in China.

In 2020, facing the challenge of the new crown epidemic, Qi Xin took over as the general manager of China, and is also the first local head of GSK.
After taking office, she led GSK China to reorganize its organizational structure and speed up the listing of many innovative products in China.

04

Chen Siyuan

General Manager of Bristol-Myers Squibb China and Hong Kong

Chen Siyuan graduated from Fudan University majoring in biochemistry and obtained an MBA degree from Columbia University Business School.
After that, he worked as a consultant at Boston Consulting Group.
After two years, he joined Novartis Pharmaceuticals and officially entered the pharmaceutical industry.
She has served as Head of Strategy and Sales and Marketing Operations Department, General Manager of Vaccine Business, Head of Strategy and Business Development Department, and Special Assistant to CEO of Global Vaccine Division in Novartis China.
After that, he served as the head of several business departments in GSK China.

In December 2019, he joined BMS as the general manager of mainland China and Hong Kong.
Last year, the entire BMS products faced fierce competition from generic drugs in China, including oncology drugs Sprycel, albumin paclitaxel, O drugs, cardiovascular drugs Eliquis, 2021 It will be a critical time node after adjustment.

05

Zhou Xiaping

Novo Nordisk Global Senior Vice President and President of Greater China

Zhou Xiaping is an executive of a multinational pharmaceutical company whose doctor turned to a pharmaceutical company.
After graduating from Shanghai Medical University, she became a doctor at Zhongshan Hospital.
In 1994, she joined Huarui Pharmaceutical as a by-product manager.
Joined Eli Lilly in 1997 and was one of the core leaders of Eli Lilly in the early development stage of the Chinese market.
During the career of Eli Lilly for more than 20 years, he has outstanding performance and good reputation.
He is known as "Chief Ke".
In 2018, he joined Novo Nordisk as global vice president and president of China.

Zhou Xiaping is a leader with both global vision and Chinese experience.
She has many years of very successful management experience in the pharmaceutical industry and has worked in overseas markets such as the United States and Malaysia for more than ten years.
Novo Nordisk China's performance increased by 9.
7% last year, accounting for 11% of Novo Nordisk’s global revenue.
Diabetes product simeglutide dominates the territory of GLP-1 hypoglycemic drugs, as well as in the fields of NASH and Alzheimer’s disease.
New drugs appear.

These women in the medical field are independent, confident, calm, and have a clear self-awareness.
They actively seek change with keen judgment and super execution in the medical field where policies are frequent and full of opportunities and challenges.
To achieve a more successful life on their own, they are also using their actions and influence to transmit the power of women.

Many outstanding business women leaders have emerged in this era.
They represent incalculable wealth and countless dreams.
I hope that more female strugglers in the pharmaceutical industry can find their own "battlefield" with their unique flexibility and firmness, and shine with their own unique light.